乳腺癌患者EC方案化疗后心电图改变分析

来源 :2016年浙江省医学会心电生理与起搏学术年会 | 被引量 : 0次 | 上传用户:ghanfeng
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  目的:分析乳腺癌患者使用EC方案化疗后的心电图改变。方法:选取60例乳腺癌患者,均使用EC方案化疗4个周期,对患者化疗前及每周期化疗后的心电图进行分析。结果:随着化疗疗程进展,心电图改变例数逐步上升,主要是ST-T改变、QRS低电压、Q-T间期延长、期前收缩、窦性心动过速、窦性心动过缓、房室传导阻滞、束支传导阻滞等。结论:常规心电图作为临床监测EC方案所致的心脏毒性是简便、实用、经济的。
其他文献
会议
目的:研究益气活血法对2型糖尿病(Type 2 diabetes mellitus,T2DM)亚临床血管病变患者颈动脉内膜中层厚度(intimal-medial thickness,IMT)、血浆血管性假血友病因子(yon Willebrand factor,vWF)、纤溶酶原激活物抑制剂-1(plasminogen activator inhibitor 1,PAI-1)的影响.方法:采用随机、
Background: Studies show different effects of the Scavenger receptor class B type 1 (SCARB1) rs5888 polymorphism in men and women,suggesting a possible mediating role of sex hormones.This meta-analysi
Background: Plasma amino-terminal pro-brain natriuretic peptide (NT-proBNP) is elevated in patients with acute heart failure (AHF).However low NT-proBNP levels were showed in selected patients with ac
Background: The RNA-binding protein Quaking(QKI),a critical post-transcriptional regulator of RNA,directly modulate various RNA metabolism processes,including pre-mRNA splicing,RNA localization,and st
目的:评价房颤合并肺心病患者射频导管消融的安全性和疗效方法:入选2014年6月至2015年9月共10例肺心病合并房颤患者,采用Ensite3000三维标测系统指导下行环肺静脉消融电隔离及左房电压高密度基质标测,评估射频消融治疗的安全性和疗效.结果:10例患者均顺利完成环肺静脉消融电隔离术,平均手术时间(157±29)min,X线曝光时间(34±17)min,随访时间(12.2±2.9)月,消融成功
Apical hypertrophic cardiomyopathy (AHCM) is a relatively rare form of hypertrophic cardiomyopathy (HCM).Moreover,apical hypertrophy is occasionally overlooked in clinical practice and usually involve
Aim: Vasa vasorum neovascularization is a key feature of atherosclerosis and is strongly associated with inflammatory infiltration,lipid deposition,intraplaque hemorrhage,and hemosiderin deposit.Here
Endostar,a novelmodified recombinant human endostatin,is nowwidely studied for the treatment of diseases that arecharacterized or caused by pathological angiogenesis.However,its molecular mechanism re
会议
Background:The effectiveness of restoring sinus rhythm by catheter ablation compared with medical rate control for persistentatrial fibrillation patients with heart failure still remains to be defined